ISRCTN22334267 https://doi.org/10.1186/ISRCTN22334267

A randomised double blind placebo controlled trial of the addition of metformin to optimal treatment in patients with chronic heart failure. Assessment by regional haemodynamics neurohumoral activation and symptomatic well being

Submission date 12/09/2003	**Recruitment status** No longer recruiting	[_] Prospectively registered [_] Protocol [_] Statistical analysis plan [_] Results [_] Individual participant data [_] Record updated in last year
Registration date 12/09/2003	**Overall study status** Completed	
Last Edited 27/10/2015	**Condition category** Circulatory System	

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr AJ Cowley

Contact details
Department of Cardiovascular Medicine
D Floor South Block
Nottingham
United Kingdom
NG7 2UH

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
N0192080686

Study information

Scientific Title
A randomised double blind placebo controlled trial of the addition of metformin to optimal treatment in patients with chronic heart failure. Assessment by regional haemodynamics neurohumoral activation and symptomatic well being

Study objectives
To determine whether metformin is of benefit in the treatment of patients with congestive heart failure.

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at time of registration

Study design
Randomised controlled trial

Primary study design
Interventional

Secondary study design
Randomised controlled trial

Study setting(s)
Not specified

Study type(s)
Treatment

Participant information sheet
Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied
Cardiovascular: Congestive heart failure (CHF)

Interventions
Randomised controlled trial.

Intervention Type
Drug

Phase
Not Applicable

Drug/device/biological/vaccine name(s)
Metformin

Primary outcome measure
1. Regional haemodynamics
2. Neurohumoral
3. Symptomatic well being

Secondary outcome measures
Not provided at time of registration

Overall study start date
15/02/2000

Completion date
31/08/2004

Eligibility

Key inclusion criteria
Total number of subjects = 20

Participant type(s)
Patient

Age group
Not Specified

Sex
Not Specified

Target number of participants
20

Key exclusion criteria
Does not match inclusion criteria

Date of first enrolment
15/02/2000

Date of final enrolment
31/08/2004

Locations

Countries of recruitment

England

United Kingdom

Study participating centre
Nottingham University Hospitals NHS Trust
Nottingham
United Kingdom
NG7 2UH

Sponsor information

Organisation
Department of Health (UK)

Sponsor details
Richmond House
79 Whitehall
London
United Kingdom
SW1A 2NL

Sponsor type
Government

Website
http://www.doh.gov.uk

Funder(s)

Funder type
Hospital/treatment centre

Funder Name
Nottingham University Hospitals NHS Trust (UK)

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration